ASTRO 2017: iCAD presents new clinical data on Xoft system for treating NMSC, early stage breast cancer

By News Release
0  Votes

iCAD, Inc. an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, has announced that external researchers will present new clinical data supporting the use of the Xoft® Axxent® Electronic Brachytherapy (eBx®) System® for the treatment of nonmelanoma skin cancer (NMSC) and early-stage breast cancer during the 2017 American Society for Radiation Oncology (ASTRO) meeting at the San Diego Convention Center in San Diego, CA from September 24-27. iCAD will also host additional presentations and a series of peer-to-peer discussion opportunities with leading eBx experts at its booth (#3139).

“We look forward to the presentation of these compelling new clinical data by leading external researchers that significantly reinforce the benefits that the Xoft System delivers to patients and physicians in the treatment of both early-stage breast cancer and nonmelanoma skin cancer,” said Ken Ferry, CEO of iCAD. “Our technology is proven to be safe and effective in appropriate patients, while offering the opportunity to treat a range of cancers using one versatile, integrated system. iCAD remains committed to providing innovative, leading-edge radiation therapies that empower physicians with full confidence to precisely and effectively treat cancer.”

In an oral presentation, Rakesh Patel, MD, radiation oncologist at Precision Cancer Specialists, will review results from a study published in the Journal of Contemporary Brachytherapy comparing the use of the Xoft System and Mohs micrographic surgery for the treatment of NMSC. 

“While Mohs surgery is considered the standard of care for NMSC, Xoft skin eBx represents an important option for many patients that can target the radiation dose directly to the cancerous site in a painless, non-invasive procedure,” said Dr. Patel. “We are excited to present these data, which add to a growing body of evidence indicating that eBx offers comparable results to Mohs surgery in appropriately selected early-stage NMSC patients.”

Nicholas Flores, MD, director of radiation oncology at Arizona Dermatology, will also present data from a study of the treatment of peri-ocular NMSC using the Xoft System. From 2013 to 2016, Dr. Flores and fellow researchers treated 86 patients with basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) of the eyelid with Xoft skin eBx. Results showed a 99 percent local control rate at two years post-treatment and no reported cases of side effects, such as long-term vision changes, dry eye, corneal injury, or retinitis.

Alam M. Nisar Syed, medical director, radiation oncology & endocurietherapy, MemorialCare Cancer Institute, Long Beach Memorial Medical Center, will also present data on the use of intraoperative radiation therapy (IORT) with the Xoft System in early-stage breast cancer patients. Dr. Syed will discuss a non-randomized, prospective, multi-center trial that involved 1,076 patients with ductal carcinoma in situ (DCIS) or invasive ductal carcinoma who met specific selection criteria and received lumpectomy followed by IORT with the Xoft System. Results showed that Xoft IORT deliver low morbidity, excellent to good cosmetic results and a low rate of high-grade adverse events and recurrences in appropriate patients.

The details of all iCAD oral and poster presentations during ASTRO are as follows:

Oral Presentations:

Title: Comparison of Electronic Brachytherapy and Mohs Micrographic Surgery – A Matched Pair Cohort Study for Treatment of Non-Melanoma Skin Cancer

Author: Rakesh Patel, MD, Precision Cancer Specialists

Date: Wednesday, September 27

Time: 7:45-9:00 am PST

Room Number: 3

Presentation Number: 263

Title: Self-reported Quality of Life in Early-stage Breast Cancer: An Ongoing Multicenter Trial of Intra-operative Electronic Brachytherapy During Breast Conservation Surgery

Author: Alam M. Nisar Syed, MD, MemorialCare Cancer Institute, Long Beach Memorial Medical Center

Date: Monday, September 25

Time: 7:45-9:00 am PST

Room Number: 5B

Presentation Number: 87

Poster Presentations:

Title: Electronic Brachytherapy at the Time of Breast Conservation Surgery for Early-Stage Breast Cancer: Early Follow-up Results of a Non-randomized, Multicenter Trial

Author: Alam M. Nisar Syed, MD, MemorialCare Cancer Institute, Long Beach Memorial Medical Center

Date: Monday, September 25

Time: 10:45-12:15 pm PST

Location: Poster Hall

Poster Number: 2116

Title: Peri-ocular non-melanoma skin cancers: Outcome in 86 cases treated with High Dose Rate Electronic Brachytherapy

Author: Nicholas Flores, MD, Arizona Dermatology

Date: Tuesday, September 26

Time: 2:45-4:15 pm PST

Location: Poster Hall

Poster Number: 2800

iCAD will also host a series of expert presentations and peer-to-peer learning opportunities in the Xoft booth (#3139) throughout the meeting. For further information, please visit http://www.xoftinc.com/astro2017.html.

Back To Top

ASTRO 2017: iCAD presents new clinical data on Xoft system for treating NMSC, early stage breast cancer.  Appl Rad Oncol. 

By News Release| September 25, 2017

About the Author

News Release

News Release

 



Copyright © Anderson Publishing, Ltd

 2017